The federal government is investigating drugmaker Cephalon Inc. over its leukemia medicine Treanda (bendamustine hydrochloride), Cephalon said in a brief Sept. 26 8-K filing with the Securities and Exchange Commission.
Cephalon said the U.S. Attorney’s Office for the Southern District of New York Sept. 23 subpoenaed records from it relating to Treanda under its authority under the Health Insurance Portability and Accountability Act. HIPAA confers subpoena authority for health care-related investigations.
Cephalon said it “is in the process of responding to the subpoena and intends to cooperate fully.”
Treanda is used to treat chronic lymphocytic leukemia, a type of cancer ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.